Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,783Revenue (TTM) $M1.3Net Margin (%)-19,432.9Altman Z-Score11.7
Enterprise Value $M1,406EPS (TTM) $-5.3Operating Margin %-19,376.5Piotroski F-Score4
P/E(ttm)--Beneish M-Score36.7Pre-tax Margin (%)-19,432.9Higher ROA y-yN
Price/Book3.810-y EBITDA Growth Rate %2.4Quick Ratio6.7Cash flow > EarningsY
Price/Sales1,0895-y EBITDA Growth Rate %36.1Current Ratio6.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-89.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-123.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M54.6ROIC % (ttm)-813.7Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-12-31 Sold Out -0.05%$12.6 - $23.56
($16.84)
$ 32.6694%Sold Out0
SRPTGeorge Soros 2014-09-30 Reduce-0.08%$19.9 - $30.27
($22.49)
$ 32.6645%Reduce -52.21%325,000
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
($31.64)
$ 32.663%Add 2620.00%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 32.6629%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 32.6610%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 32.66-15%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 32.6613%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 32.6622%Add 184.13%226,429
SRPTFirst Eagle Investment 2012-03-31 Sold Out $4.44 - $9.6
($6.51)
$ 32.66402%Sold Out0
SRPTFirst Eagle Investment 2011-12-31 Reduce$3.24 - $6.54
($4.96)
$ 32.66558%Reduce -83.33%8,333
SRPTFirst Eagle Investment 2011-09-30 Add$6.3 - $9.9
($7.86)
$ 32.66316%Add 50.00%50,000
SRPTFirst Eagle Investment 2011-06-30 Buy $8.1 - $11.22
($9.69)
$ 32.66237%New holding33,333
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Mahatme SandeshSenior Vice President, CFO 2016-10-17Sell30,000$50.08-34.78view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-22Sell40,179$60-45.57view
Howton David TSVP, General Counsel 2016-09-22Sell7,000$60-45.57view
Ruff ShamimSVP, Regulatory Affairs & Qual 2016-09-22Sell7,311$60-45.57view
Aphale JayantVP, Technical Operations 2016-09-19Sell35,000$50-34.68view
Kaye Edward M. MDPresident, CEO & CMO 2016-09-19Sell24,352$50-34.68view
Howton David TSVP, General Counsel 2016-09-19Sell9,304$50-34.68view
Kaye Edward M. MDSVP Interim CEO & CMO 2016-09-14Sell24,557$308.87view
BEHRENS M KATHLEENDirector 2016-03-16Buy75,000$16.28100.61view
Barry RichardDirector 2016-03-14Buy75,000$15.66108.56view

Quarterly/Annual Reports about SRPT:

News about SRPT:

Articles On GuruFocus.com
Sarepta Shares Tumble Following FDA Committee's Decision Apr 26 2016 
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
Sarepta Drug Gets UnitedHealth Coverage (SRPT, UNH) Dec 02 2016
New Aetna Clinical Policy Bulletin Details 'Medical Necessity' Of Sarepta's Exondys 51 Dec 02 2016
5 Medical Tech Stocks You Should Be Investing In Dec 01 2016
Sarepta: UnitedHealth Induced Selloff a Buying Opportunity? Dec 01 2016
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 30 2016
The 21st Century Cures Act Will Not Fix The FDA Nov 30 2016
Sarepta Therapeutics: A Mistake to Underestimate Its Sales, Baird Says Nov 29 2016
Aetna Still Undecided On Coverage For Sarepta's Highly Debated Muscular Dystrophy Treatment Nov 21 2016
SAREPTA THERAPEUTICS, INC. Financials Nov 17 2016
3 Stocks to Add to Your Portfolio as Biotech M&A Hopes Rise Nov 17 2016
How Donald Trump May Impact The FDA Nov 14 2016
​Why not everyone is buying the market hype surrounding Sarepta’s Duchenne drug Nov 11 2016
3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High' Nov 11 2016
PTC Therapeutics Duchenne Drug Wins Extended European Approval Nov 11 2016
Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other... Nov 08 2016
SAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2016
Sarepta Therapeutics to Present Company Overview at the Credit Suisse 25th Annual Healthcare... Nov 04 2016
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 02 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)